Log ind
Genmab_logo_silver_on_green.jpg

Genmab buys antibodies from BMS

Top picks in English:

Genmab has signed a deal with US-based drug group Bristol-Myers Squibb, giving the biotech an exclusive license to an antibody panel aimed at a specific cancer target.


BY LONNI LYNGE
Offentliggjort 03.06.15 kl. 16:08

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Danish hearing aid giants in global showdown

Unavngivet.jpg Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

BMS signs fibrosis deal with Danish biotech company

Top picks in English:

A Danish biotech company is now going to develop biomarkers for US-based drug group Bristol-Myers Squibb to potentially aid in diagnosing and monitoring fibrotic diseases, including fatty liver disease NASH.

Bavarian Nordic signs new commercial agreement

Top picks in English:

The Danish biotech company enters into a partnership with French counterpart which ensures Bavarian Nordic the rights to develop and commercialize new poxvirus-based vaccines.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Danish biotech company goes courting

Top picks in English:

The small Danish biotech company Mipsalus is on the prowl for a partner to help it bring its drug to treat the hereditary metabolic condition phenylketonuria (PKU) into the clinic and onto the market as fast as possible.

Global venture boss keeps an eye on Danish biotech companies

Top picks in English:

Omega Funds receives 2200 applications from life science companies per year and 99.9 percent of these are turned down. But some Danish biotech companies have caught the attention of founder Otello Stampacchia and might be among the 0.1 lucky ones.

Forsiden lige nu

Alligator sulten efter nye udviklingsmuligheder efter to store milepæle

COLOURBOX14303691.jpg Medicinal & Biotek:

Med en veloverstået børsnotering og en lukrativ partneraftale med Janssen under bæltet, retter det Sunstone-støttede Alligator nu opmærksomheden indad mod de næste tre lovende lægemiddelkandidater.

Nordjysk rehabkomet rider stolelift til høj vækst

Medico & Rehab:

Det danske rehabselskab Liftup fortsætter sin flotte vækstrate, særligt hjulpet af den transportable stolelift Raizer, hvor salget er steget med hele 59 pct.

Genmabs Arzerra-partner rammer over forventningerne

Medicinal & Biotek:

Schweiziske Novarts har gjort det bedre end ventet i årets første kvartal, selvom der er tilbagegang i resultatet.

Bank sænker anbefaling på Össur

Medico & Rehab:

Nordea ser begrænset potentiale på kort sigt i det islandske proteseselskab Össur og nedgraderer derfor sin anbefaling af selskabets aktie.

Trump vil sænke selskabsskatten

Medicinal & Biotek:

USA's virksomheder skal slippe med 15 pct. i skat, hvis det står til Donald Trump, og det vil også gavne de danske medicinalselskaber, der har forretning i landet. Flere af hans partifæller er dog skeptiske.

Tre lande tester GSK-vaccine mod malaria

Medicinal & Biotek:

Næste år kan børn i Ghana, Kenya og Malawi vaccineres mod malaria fra medicinalvirksomheden GlaxoSmithKline. Over 400.000 dør årligt af sygdommen.

ANNONCE
ANNONCE


ANNONCE